Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug2528 | Matching placebo Wiki | 0.35 |
drug3195 | Placebo Wiki | 0.03 |
Name (Synonyms) | Correlation | |
---|---|---|
D004760 | Enterocolitis NIH | 0.71 |
D011014 | Pneumonia NIH | 0.04 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0004387 | Enterocolitis HPO | 0.71 |
HP:0002090 | Pneumonia HPO | 0.04 |
Navigate: Correlations HPO
There are 2 clinical trials
The study will assess the efficacy and safety of MAS825 for the treatment of SARS-CoV-2 infected patients with COVID-19 pneumonia and impaired respiratory function
Description: The APACHE II ("Acute Physiology And Chronic Health Evaluation II") is a severity-of-disease classification system. An integer score from 0 to 71 is computed based on several measurements; higher scores correspond to more severe disease and a higher risk of death. Worst case imputation for death will be applied.
Measure: APACHE II severity of disease score on Day 15 or on day of discharge (whichever is earlier) Time: Up to 15 daysDescription: C-reactive protein (CRP) is a blood test marker for inflammation in the body. For a standard CRP test, a normal reading is less than 10 milligram per liter (mg/L). It will be analyzed on a logscale fitting a repeated measures mixed model including treatment group, study day, the three stratification factors and log transformed baseline CRP as a covariate.
Measure: Serum C-reactive protein (CRP levels) Time: Up to 15 daysDescription: Ferritin is a blood test marker for inflammation in the body. For a standard Ferritin test, a normal reading is less than 300 micrograms per liter (μg/L). It will be analyzed on a logscale fitting a repeated measures mixed model including treatment group, study day, the three stratification factors and log transformed baseline Ferritin as a covariate.
Measure: Ferritin levels Time: Up to 15 daysDescription: Proportion of participants without the need for invasive mechanical ventilation for survival.
Measure: Proportion of participants without the need for invasive mechanical ventilation Time: Day 15, Day 29Description: Clinical status is measured with the 9-point ordinal scale. The scoring is - Uninfected patients have a score 0 (no clinical or virological evidence of infection). - Ambulatory patients (not in hospital or in hospital and ready for discharge) can have a score 1 (no limitation of activities) or 2 (limitation of activities). -Hospitalized patients with mild disease can have score 3 (no oxygen therapy defined as SpO2 ≥ 94% on room air) or 4 (oxygen by mask or nasal prongs). - Hospitalized patients with severe disease can have score 5 (noninvasive ventilation or highflow oxygen), 6 (intubation and mechanical ventilation) or 7 (ventilation + additional organ support - pressors, RRT (renal replacement therapy), ECMO (extracorporeal membrane oxygenation)). - Patients who die have a score 8.
Measure: Proportion of participants with at least one level improvement in clinical status Time: Day 15, Day 29Description: Clinical status is measured with the 9-point ordinal scale. The scoring is - Uninfected patients have a score 0 (no clinical or virological evidence of infection). - Ambulatory patients (not in hospital or in hospital and ready for discharge) can have a score 1 (no limitation of activities) or 2 (limitation of activities). -Hospitalized patients with mild disease can have score 3 (no oxygen therapy defined as SpO2 ≥ 94% on room air) or 4 (oxygen by mask or nasal prongs). - Hospitalized patients with severe disease can have score 5 (noninvasive ventilation or highflow oxygen), 6 (intubation and mechanical ventilation) or 7 (ventilation + additional organ support - pressors, RRT (renal replacement therapy), ECMO (extracorporeal membrane oxygenation)). - Patients who die have a score 8.
Measure: Clinical status over time Time: Up to 15 daysThis study is a Phase 2 trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 in patients with NLRC4-GOF
Description: To determine the efficacy of MAS825 in prevention of flares in NLRC4-GOF patients
Measure: Occurrence of disease flare in patients with MAS825 treated patients compared with placebo during Period 2 assessed by Physician's Global Assessment and inflammatory markers Time: Period 2Description: To evaluate the safety and tolerability in patients with NLRC4-GOF
Measure: Number and severity of safety assessments and adverse events Time: Screening through EOS (End of Study)Description: Evaluate the serological markers of MAS825
Measure: Confirmation of serological markers of MAS825 Time: Until End of StudyDescription: Evaluate efficacy of MAS825 to improve clinical status of NLRC4-GOF patients
Measure: PGA and inflammatory markers at Day 29, end of Period 1 and 2 Time: Day 29, end of Period 1, end of Period 2Description: Evaluate efficacy of MAS825 to achieve serological remission
Measure: Serological remission via inflammatory markers Time: Day 29, end of Period 1, and end of Period 2Description: Evaluate the effect of MAS825 on concomitant glucocorticoid administration
Measure: Glucocorticoid therapy <0.2mg/kg by end of period 1 Time: End of Period 1Description: Evaluate effect of MAS825 on the time to first flare in patients with NLRC4-GOF
Measure: Time to first flare during period 2 Time: Period 2Description: Evaluate the efficacy of MAS825 to improve signs and symptoms of NLRC4-GOF
Measure: Physician Severity Assessment of Disease Signs and Symptoms scale Time: Screening through EOSDescription: Evaluate effect of MAS825 on patient reported outcomes in patients with NLRC4-GOF over time
Measure: Patient' / Parent's global assessment of disease activity (PPGA) scale Time: Screening through EOSAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports